Recent Conference Coverage
Recent trial data indicate that axillary lymph node dissection (ALND) can be safely omitted in select patients, according to a research presented at the 2015 San Antonio Breast Cancer Symposium.
The use of sentinel lymph node biopsy (SLNB) alone for care for axillary management in breast cancer patients with negative nodes is on the increase, according to study data presented at the 2015 San Antonio Breast Cancer Symposium.
New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.
A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.
Ten-year Overall Survival Is Higher After Breast-conserving Therapy Compared With Mastectomy in Early Stage Breast Cancer
Breast-conserving surgery with radiation therapy (BCT) demonstrated improved 10-year overall survival in patients with early stage breast cancer compared with mastectomy without radiation therapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
EPclin Score Provides More Prognostic Information for Residual Distant Recurrence in ER+/HER2- Breast Cancer
EndoPredict (EP) provided superior information to the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N- patient populations, and also pinpointed a low-risk patient group who may not need chemotherapy.
Synthetic 2D Mammography Is Cost Effective and Reduces X-ray Exposure in Breast Cancer Screening Mammography
Use of a synthetic 2D mammogram, instead of a standard 2d film, may offer breast cancer patients the benefits of 2D/3D screening combinations at a reduced radiation exposure level.
Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free Survival
Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.
Premenopausal Patients With High-risk Luminal A Breast Cancer Get No Benefit From Adjuvant Chemotherapy
Premenopausal women with luminal A subtype breast cancer had comparable 10-year disease-free survival rates regardless of whether they received adjuvant chemotherapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
Avelumab has an acceptable safety profile in patients with metastatic breast cancer and demonstrated signs of greater clinical activity in specific subsets of patients.
Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL
For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.
A recent study examined the direct and indirect costs for patients with relapsed or refractory multiple myeloma.
Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.
Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.
Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.
A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.
In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.
The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.
PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.
Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
No difference in local efficacy was found between two treatment regimens for colorectal cancer: short-course (5-day) radiation followed by consolidation chemotherapy before surgery and standard 5-week chemoradiation.
The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.
Survivorship care plans led to improved outcomes in a randomized, controlled trial reported at the American Society of Clinical Oncology 2016 Cancer Survivorship Symposium.
Adolescent and Young-adult Survivors of Hodgkin Lymphoma May Not Adhere to Follow-up Recommendations
Within the first year posttreatment, more than half of Hodgkin lymphoma survivors did not receive all recommended care. However, 96% had their recommended oncology visits and 70% had the recommended laboratory tests within the first 5 years.
A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.
Data collected from Japanese and Korean participants in the global PALOMA3 trial provide evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with advanced HR+/HER2- breast cancer.
LUX-Lung 7 Trials Shows Afatinib Achieves Better Response Than Gefitinib in Patients With EGFR-mutated Lung Cancer
In the global, randomized, open-label phase IIb LUX-Lung 7 trial, efficacy across a range of clinically relevant end points, such as progression-free survival, time-to-treatment failure, and objective response rate, was significantly improved with afatinib vs. gefitinib.
Glioma Cells Self-organize Into Streams of Cells That Follow a Mathematically Predicted Pattern to Build Brain Tumors
Brain tumor cells can self-organize, according to new research. Glioma cells build tumors by self-organizing into streams 10 to 20 cells wide that obey a mathematically predicted pattern for autonomous agents flowing together.
Association Is Found Between Bone Complications in Young Pediatric Patients With Leukemia and Gene Variations
Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL).
- Novel Procedure Improves Staging of Lymph Nodes in Patients With Breast Cancer
- Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis
- Risk of Breast Cancer or Thyroid Cancer Higher Following a Diagnosis of the Other Cancer Type
- Nab-paclitaxel Increases Complete Response Rate in Invasive Breast Cancer
- Satisfaction With Navigators Associated With Satisfaction With Cancer-related Care
- Understanding Drug Naming Nomenclature
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Inconclusive: The Pulmonary Nodules You Need to Follow
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Novel Procedure Improves Staging of Lymph Nodes in Patients With Breast Cancer
- Tailoring Decisions on Radiation Therapy for DCIS
- Skeletal-related Events Linked With Worse Survival, Increased Costs
- Exercise Intervention Fails to Improve Physical Functioning in Advanced Breast Cancer
- PET Imaging Promising for Metastatic Prostate Cancer
- Families of Patients With Cancer Seek Information More Than Support on Internet
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|